ABSTRACT Background. Population-based studies comparing minimally invasive esophagectomy (MIE) and open esophagectomy (OE) relative to 90-day postoperative mortality are needed. Objective. The aim of this study was to compare shortterm outcomes following these two techniques for esophageal cancer. Methods. Patients undergoing MIE (n = 217) or OE (n = 1397) for esophageal cancer between 2007 and 2014 were identified from nationwide complete registries in Finland and Sweden. The primary outcome was 90-day mortality, and secondary outcomes were 30-day mortality, length of hospital stay, and 30-and 90-day readmission rate. Results were adjusted for age, sex, comorbidity, tumor histology, surgery year, and country. Results. Ninety-day mortality rates were 4.1% (n = 9 of 217) for MIE and 6.8% (n = 95 of 1397) for OE; 90-day mortality was halved after MIE [adjusted hazard ratio (HR) 0.49, 95% confidence interval (CI) 0.24-0.99]. There was no difference in 30-day mortality (adjusted HR 0.87, 95% CI 0.29-2.66). Median hospital stay was 15 days for MIE and 16 days for OE (adjusted b -0.17, standard error 0.08, p = 0.030). The 30-day readmission rates were 8.9% after MIE and 12.0% after OE (adjusted HR 0.57, 95% CI 0.34-0.94), while the 90-day readmission rates were 28.8% and 33.6%, respectively, without a statistically significant difference (adjusted HR 0.82, 95% CI 0.61-1.10).
Esophageal cancer is the sixth leading cause of cancer death worldwide, 1 with surgery offering the best chance for cure in early or locally advanced disease. 2 Esophagectomy is an extensive operation with considerable risks of morbidity and mortality. To reduce complications, the use of minimally invasive esophagectomy (MIE) has increased during the last years. 3 One randomized study and several single-center series suggest that MIE reduces postoperative morbidity, shortens hospital stay, and improves patient satisfaction compared with open esophagectomy (OE) without compromising the long-term oncological outcomes. [4] [5] [6] [7] [8] [9] [10] However, these findings originate from high-volume surgeons at high-volume centers, which does not necessarily reflect the results at the population level. Two population-based national studies, one from the UK and one from Japan, found no differences in 30-day mortality or morbidity between MIE and OE, but the reoperation rate within 30 days of surgery was higher after MIE in both studies. 11, 12 Similarly, when compared with OE, MIE was not associated with lower rates of complications or 30-day mortality, but rather with a higher reoperation rate in a study from the US. 13 The 30-day mortality rate after esophagectomy has been approximately 4-5% in several European countries and the US, 11, 14 but risk of mortality persists beyond the traditional 30-day mortality assessment. 15 Therefore, 90-day mortality is increasingly considered to be a better short-term outcome measure for major surgery, [14] [15] [16] yet no population-based study comparing the 90-day outcomes between MIE and OE hasbeen reported. In a nationwide French study, lower 90-day mortality has been reported after a hybrid procedure. 17 We conducted a population-based, nationwide study in Finland and Sweden with the aim of testing whether MIE or OE provide better 90-day outcomes following esophagectomyfor esophageal cancer in an unselected cohort of patients.
METHODS

Design
All patients who underwent MIE or OE for cancer of the esophagus or gastroesophageal junction in Finland or Sweden from 2007 through 2014 were eligible for this population-based, nationwide cohort. The two approaches were compared regarding 90-day all-cause mortality as the main outcome, while 30-day all-cause mortality, length of hospital stay, and readmission rates within 30 and 90 days of surgery were secondary outcomes. The National Institute for Health and Welfare of Finland (permission numbers THL/143/5.05.00/2015 and THL/1349/5.05.00/ 2015) and the Regional Ethical Review Board in Stockholm, Sweden (DNR-2015/1916-31/1 and 2016/584-32) approved the study.
Data Collection
All residents in both countries have unique and immutable 10-or 11-digit national registration numbers, which allows for a high identification rate of patients from hospital records, administrative databases, and national health data registries, and makes the unification of these databases reliable. In this study, patients who underwent esophagectomy for esophageal cancer between 1 January 2007 and 2 October 2014 were retrospectively identified from the Care Register for Healthcare in Finland and the Cancer Registry and Patient Registry in Sweden. All patients were followed-up until 90 days postsurgery, death, or emigration. Follow-up ended on 31 December 2014. Mortality data were linked for each patient individually from Statistics Finland and from the Swedish Causes of Death Registry. These registries had complete nationwide coverage during the study period and reporting to the registries is compulsory in Finland and Sweden. Coverage of the Finnish Hospital Discharge Registry and the Swedish Patient Registry are also high because of the legislative obligation of reporting and the relationship of reporting, as well as hospital funding. The Finnish Cancer Registry has a nationwide coverage of over 99%, 18 while the Swedish Cancer Registry has at least 98% nationwide coverage for all esophageal cancers. 19 The Finnish Hospital Discharge Registry and Care Register for Healthcare, as well as the Swedish Patient Registry, were also used to obtain data on patients' medical comorbidities, readmissions, and lengths of hospital stay. Data recorded in each of these registers are reliable in both Finland 20 and Sweden, 21 and the complete reporting of the discharge codes is encouraged by its relationship to hospital funding. Furthermore, all hospitals are obligated by legislation to annually report every inpatient treatment period and all outpatient contacts. Each healthcare contact is provided with baseline data (including age, sex, and speciality of healthcare contact), data on length of hospital stay, performed procedures, and discharge diagnoses and complications. The Charlson comorbidity index was calculated from diagnoses in the registries in 2004-2014, according to a validated algorithm, 22 but excluding esophageal cancer. Gastric cancer was also excluded from the comorbidity index because the diagnoses of distal esophageal and proximal gastric cancer can overlap in the diagnostic phase. 19 Standard procedures in Finland and Sweden during the study period were either Ivor-Lewis esophagectomy with intrathoracal anastomosis, or McKeown procedure with cervical anastomosis in both MIE and OE, with the majority performed according to the Ivor-Lewis method.
23,24
Statistical Analysis
Baseline characteristics were analyzed using Chi-square or analysis of variance (ANOVA) tests as appropriate. Kaplan-Meier survival curves were calculated according to the life table method to visualize the crude all-cause mortality and readmission rates within 90 days of surgery. Cox regression was used for calculating the relative risks of mortality and readmissions, and linear regression was used in analyses of length of hospital stay (logarithmically transformed due to skewness). OE was used as the reference group in all these analyses. The regression models were adjusted for six covariates that were considered as potential confounding factors: age (continuous variable), sex (male or female), Charlson comorbidity score (0, 1, 2, 3-5, or C 6), histological tumor type (adenocarcinoma or squamous cell carcinoma), year of the surgery (each year between 2007 and 2014), and country (Finland or Sweden). As MIE was only conducted in higher-volume hospitals, adjustment for hospital volume was not feasible. Instead, a subgroup analysis was performed with the previously mentioned adjustments for patients only operated on in hospitals performing both MIE and OE. Patients who died during hospital admission for esophagectomy were censored from the length of hospital stay analysis. Patients who died within the first 30 days of surgery were censored from the analysis of 30-day readmissions, and patients who died during 90 days were censored from 90-day readmissions. All analyses were conducted using the statistical software SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Patients
Between January 2007 and October 2014, 1614 patients underwent esophagectomy for esophageal cancer in Finland or Sweden, including 217 (13%) with MIE and 1397 (87%) with OE (Table 1) . Among the 35 hospitals conducting esophagectomies during the study period, a total of 11 hospitals performed both MIE (n = 217) and OE (n = 873). The mean age at surgery was 64.8 years. Most patients (53%) had no reported comorbidity (Charlson comorbidity score of 0) and adenocarcinoma histology (74%); patients in the MIE group had less comorbidity than those in the OE group (65% vs. 51% had no comorbidity, p = 0.006). The proportion of patients with MIE increased during the study period, but otherwise there were no major baseline differences between comparison groups (Table 1) .
90-Day Mortality
The 90-day mortality rate was 4.1% in the MIE group and 6.8% in the OE group (Fig. 1) , and the adjusted risk of 90-day mortality was reduced by 51% after MIE compared with OE (HR 0.49, 95% CI 0.24-0.99) ( Table 2 ). In a subgroup analysis of patients operated in hospitals performing both MIE and OE only, the 90-day mortality rate was 4.1% in the MIE group and 6.0% in the OE group, with an adjusted HR of 0.54 (95% CI 0.24-1.18) when comparing MIE with OE.
30-Day Mortality
The 30-day mortality rate for all patients was 1.8% following MIE and 1.9% for OE (Fig. 1) , with no difference in risk when comparing MIE and OE (adjusted HR 0.87, 95% CI 0.29-2.66) ( Table 2 ).
The subgroup analysis of patients operated in hospitals conducting both MIE and OE showed similar findings, with an adjusted HR of 0.77 (95% CI 0.22-2.67).
Hospital Stay
The median length of hospital stay was 15 days after MIE and 16 days after OE, and the crude linear regression analysis showed no difference between the groups. However, the adjusted analysis revealed a reduced length of hospital stay after MIE compared with OE (p = 0.03) ( Table 3 ). The median hospital stay in the subgroup analysis after surgery in hospitals performing both MIE and OE was slightly shorter after MIE (15 days) than after OE (17 days), and the difference was statistically significant in the adjusted analysis (p = 0.01).
Readmissions After Surgery
Within the first 30 postoperative days, 8.9% of patients were readmitted after MIE, compared with 12.0% after OE. The adjusted HR for 30-day readmission was reduced after MIE compared with OE (HR 0.57, 95% CI 0.34-0.94) ( Table 4) , and the proportion of patients readmitted within 90 postoperative days was 28.8% after MIE and 33.6% after OE, but the adjusted analysis showed no statistically significant difference (HR 0.82, 95% CI 0.61-1.10) ( Table 4) .
In the subgroup analysis of patients operated on in hospitals conducting both MIE and OE, 8.9% of MIE patients and 9.9% of OE patients were readmitted within the first 30 postoperative days, and the adjusted HR was 0.71 (95% CI 0.40-1.27). The HR for 90-day readmission was similar to that found in the main analysis (HR 0.87, 95% CI 0.62-1.22).
DISCUSSION
The results of the present study suggest that, for esophageal cancer, MIE is followed by a lower 90-day mortality rate compared with OE. MIE was also associated with a slightly shorter length of hospital stay and lower 30-day readmission rate compared with OE.
The main strength of this study is the population-based design with complete nationwide data from two Nordic countries, including complete follow-up of all patients. This design counteracted selection bias, which is otherwise a frequent issue in retrospective studies. The design also provides an opportunity to assess the differences between MIE and OE in general practice, which might not be the case in clinical trials or reports from single, high-volume centers. On the other hand, confounding is a limitation of the observational study design. We took this into account by adjusting for various potential confounding variables such as age, comorbidity, and histology. The lack of information about tumor stage could also introduce confounding because the MIE group might include more earlystage tumors. However, short-term mortality rates are highly specific to surgery-related deaths and not tumor stage in esophageal cancer surgery, 16, 25 therefore the influence of tumor stage should be limited. Another concern is the lack of data on complications. However, we used length of hospital stay and readmission rates as proven reliable proxies for complications. 26 Due to the lack of separate coding, the register data could not differentiate totally minimally invasive surgery from a hybrid procedure. This fact and the inclusion of the learning curve phase of MIE in both countries should dilute the beneficial effects of MIE rather than favor minimally invasive surgery. On the other hand, MIE is more likely to be conducted by high-volume centers and surgeons, and confounding by surgeon or hospital volume could be a (17) 251 (18) 27 (12) 2 178 (11) 159 (11) 19 (9) 3-5 115 (7) 102 (7) 13 (6) C 6 192 (12) 174 (12) 18 (8) Tumor histology a Adenocarcinoma 1199 (74) 1031 (74) 168 (77) Squamous cell carcinoma 372 (26) 333 (26) 39 (23) Year of surgery 2007 185 (11) 184 (13) 1 (0) 2008 174 (11) 168 (12) 6 (3) 2009 196 (12) 182 (13) 14 (6) 2010 218 (14) 189 (14) 29 (13) 2011 211 (13) 187 (13) 24 (11) 2012 209 (13) 178 (13) 31 (14) 2013 239 (15) 197 (14) 42 ( problem. 27 However, the subgroup analyses of only hospitals conducting both MIE and OE showed similar results to that found in the main analysis, suggesting that the observed risk reduction by MIE versus OE was not due to bias by surgeon or to hospital volume. Finally, chance could have influenced the results, particularly in the subgroup analyses, but chance errors are unlikely to be explanations for the identified positive associations.
A French population-based study previously reported lower 90-day mortality after a hybrid procedure, suggesting beneficial effects of laparoscopic gastric mobilization compared with laparotomy during esophagectomy. 17 To our knowledge, the current study is the first to compare totally MIE and OE for esophageal cancer using 90-day mortality at a national level. The findings presented here of decreased 90-day, but not 30-day, mortality following MIE compared with OE support the notion that 90-day mortality might be a better short-term outcome measure than 30-day mortality in esophageal cancer surgery. 15 Previous studies have suggested that MIE reduces postoperative complications (especially pulmonary complications), 9, 28 which may explain the reduced mortality after MIE identified in the present study. The similar 30-day mortality rates are in line with the findings seen in previous population-based studies. 11, 12 In this study, 90-day mortality rates were substantially higher than 30-day mortality rates for MIE (1.8% vs. 4.1%), and even more so for OE (1.9% vs. 6.8%). Similar increases have 14, 15, 17 Deaths occurring between 30 and 90 days of surgery are usually related to the operation, with anastomotic leakage being the single most common cause of mortality. 16 Complications are treated intensively and patients could survive beyond the initial 30 days due to improved perioperative care.
The median length of hospital stay in the current study was shorter after MIE compared with OE; however, no such difference in length of stay has been identified in studies from Japan and England. 11, 12 Nonetheless, in a nationwide French study, hospital stay was reduced by 2 days after laparoscopic gastric mobilization. 17 Furthermore, a randomized study comparing MIE and OE conducted in high-volume centers suggested a reduction of hospital stay by 3 days after MIE. 9 Moreover, a US database study suggested a reduction of hospital stay by 1 day, 29 with similar results being found in a Finnish single-center study. 24 The reduction in the present study is therefore well in line with previous literature.
In the present study, MIE was associated with fewer readmissions at 30 days, while the rates of readmissions were similar between the surgical approaches within 90 days of surgery. The lower rate of readmissions at 30 days after MIE could be explained by the better recovery and less pain observed after MIE. 30, 31 Previous studies have reported 7-13% 30-day readmission rates, with no difference between the approaches. 11, 29 No 90-day readmission rates have been previously reported at the national level. The high 90-day readmission rate in the present study could be due to cancer management, i.e. the start of perioperative chemotherapy.
The findings in this study could have clinical and research implications. An important foundation for the comparison of MIE and OE is the recent finding in the randomized TIME trial showing equal overall and diseasefree survival between MIE and OE. 10 Therefore, the observed reduction in early mortality, shorter hospital stay, and lower readmission rates suggests MIE as a primary surgical method for esophageal cancer. Whether MIE could be safely used for patients medically unfit for open esophageal surgery with acceptable short-term mortality and morbidity remains to be studied.
CONCLUSION
This population-based study from the entirety of Finland and Sweden indicates lower 90-day mortality, shorter hospital stay, and reduced rate of readmissions after MIE compared with OE. These findings support the use of MIE in esophageal cancer surgery. 
